Token economy, pimozide and chronic schizophrenia

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Schizophrenia is a chronic mental disorder impacting cognition and behavior.
• Token economies are used to incentivize positive behaviors in psychiatric settings.
• Antipsychotic medications are a cornerstone of schizophrenia treatment.

Purpose of the Study:

• To compare the efficacy of pimozide and chlorpromazine in male chronic schizophrenic inpatients within a token economy system.
• To evaluate the impact of these antipsychotics on both general ward behavior and specific token-rewarded target behaviors.

Main Methods:

• A double-blind, cross-over trial was conducted over six months.
• Patients received either pimozide (up to 20 mg/day) or chlorpromazine (up to 1000 mg/day) for three months each.
• Behavioral assessments focused on general ward conduct and token-rewarded target behaviors.

Main Results:

• Significant improvements were observed in general ward behavior and token-rewarded target behaviors after six months.
• No statistically significant differences were found between pimozide and chlorpromazine.
• A trend suggested pimozide may be more effective for general ward behavior, while chlorpromazine showed no specific advantage.

Conclusions:

• Both pimozide and chlorpromazine can enhance behavioral outcomes in schizophrenic patients within a token economy.
• Patient cooperation and initiative correlated positively with satisfactory token-rewarded behavior.
• Further research could explore differential effects on specific behavioral domains.